AM-PHARMA PROVIDES BUSINESS UPDATE AND OUTCOME OF PRE-PLANNED INTERIM FUTILITY ANALYSIS OF PHASE 3 REVIVAL STUDY

Phase 3 REVIVAL study stopped per recommendation of data monitoring committee after per-protocol pre-specified interim futility analysis on the study’s primary endpoint, 28-day mortality, without any safety concern. A significant reduction in Major Adverse Kidney Events by day 90 and no difference in overall mortality was observed after review of the data for all 649 […]

AM-PHARMA ANNOUNCES PUBLICATION OF IN VIVO ACUTE KIDNEY INJURY STUDY DEMONSTRATING ILOFOTASE ALFA’S DUAL PROTECTIVE MECHANISM

Study shows ilofotase alfa protects against ischemia-reperfusion induced acute kidney injury in rodents through the activation of adenosine receptors and the metabolism of extracellular adenosine triphosphate (ATP), a pro-inflammatory molecule Utrecht, The Netherlands, 05 July 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced new data indicating […]

AM-Pharma to Participate in Upcoming Jefferies Healthcare Conference

Utrecht, The Netherlands, June 6, 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Lars Boesgaard, Chief Financial Officer, is scheduled to present at the Jefferies Healthcare Conference, being held in New York, NY on Wednesday, June 8th, 2022 at 8:00 AM ET. About AM-Pharma AM-Pharma’s purpose […]

400 PATIENTS HAVE BEEN ENROLLED IN AM-PHARMA’s PIVOTAL PHASE 3 STUDY OF ILOFOTASE ALFA FOR THE TREATMENT OF SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY

Decision from the first pre-specified futility analysis at 400 patients is expected in July Utrecht, The Netherlands, April 25, 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that 400 patients have now been enrolled in the main trial population in the pivotal Phase 3 REVIVAL study. […]

AM-Pharma to Participate in SVB Leerink Biopharma Private Company Connect

Utrecht, The Netherlands, March 22, 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Erik van den Berg,  Chief Executive Officer, and Lars Boesgaard, Chief Financial Officer, are scheduled to participate in SVB Leerink’s Biopharma Private Company Connect on Tuesday, March 29th, 2022. The company will be […]

AM-PHARMA ANNOUNCES TWO PRESENTATIONS AT THE 27TH INTERNATIONAL CONFERENCE ON ADVANCES IN CRITICAL CARE NEPHROLOGY

The lead investigator will present an overview of AM-Pharma’s ongoing Phase 3 REVIVAL study at 11:30 AM PT (2:30 PM ET) on Thursday, March 10, 2022; and New data underscoring the correlation between acute kidney injury severity and patient outcomes following cardiac surgery will be presented in a poster session today San Diego, California and […]

AM-Pharma to Participate in Upcoming Investor and Scientific Conferences

UTRECHT, The Netherlands – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that members of its senior management team are scheduled to participate in the following investor conferences: Cowen 42nd Annual Healthcare Conference on Wednesday, March 9, 2022. The Company will be conducting investor meetings, which can be […]

AM-Pharma and Leading Experts Publish Report on State-of-the-Art Clinical Trials in Acute Kidney Injury

Utrecht, The Netherlands, January 26, 2022 – AM Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that its Chief Operating Officer, Juliane Bernholz, PhD, is among the authors of a recently published peer-reviewed article discussing the design and implementation of clinical trials for Acute Kidney Injury (AKI). With representation […]

AM-Pharma to Participate in Upcoming Investor Conferences

Utrecht, The Netherlands, January 5, 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Erik van den Berg, the Company’s Chief Executive Officer, and Lars Boesgaard, Chief Financial Officer, will participate in the following investor conferences: Kempen’s 40th Annual Life Sciences Virtual Crossover Conference on Thursday, January […]

AM-Pharma Appoints Alexander Bastian as Vice President Value & Market Access

Utrecht, The Netherlands, 3 November, 2021 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced the appointment of Alexander Bastian as Vice President Value & Market Access, effective immediately. Mr. Bastian joins the company with over 19 years of leadership in product launch and market access strategies from […]